MVP.ASX: Appendix 4C and Quarterly Activity Report 30 June 2026

Appendix 4C and Quarterly Activity Report 30 June 2026

Stock	Medical Developments International Ltd (MVP.ASX)
Release Time	24 Jul 2026, 8:24 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

MVP.ASX Releases Q4 FY26 Quarterly Activity Report

Key Points

Positive free cashflow for Q4 and full year FY26
Penthrox revenue up by $5.4 million for the full year
Penthrox volume growth of 28% in the Australian hospital segment
Cash balance at 30 June 2026 of $21.4 million
Paediatric label for Penthrox approved and launched in UK and EU

Full Summary

Medical Developments International Ltd (ASX: MVP) has released its Appendix 4C and Quarterly Activity Report for the quarter ended 30 June 2026 (Q4 FY26). The report highlights positive free cashflow for both Q4 and the full financial year. Penthrox revenue increased by $5.4 million for the full year. Volume growth was notable, with a 28% increase in the Australian hospital segment and an 18% increase in European markets. The paediatric label for Penthrox was approved and launched in the UK and all European markets, expanding the product's addressable market. The company's cash balance stood at $21.4 million at 30 June 2026. CEO Brent MacGregor emphasized the company's focus on growing Penthrox volume while improving margins and reducing overheads.

Guidance

FY26 EBIT expected to be modestly improved on FY25

Outlook

The company expects to see benefits from access to the broader addressable market in future periods, following the expansion of Penthrox's paediatric indication.